Sandford D Smith
CIK 1243004 · Chief Executive Officer · last filed 2024-01-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYTK | Director | 18,801 | $60.77 | $1.14M | -$6.69M | 54 | 2024-01-03 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Director | — | — | — | $0 | 4 | 2020-10-13 |
| PALISADE BIO, INC. (CUR) Delisted | Director | 10,996 | — | — | $0 | 5 | 2019-07-03 |
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | Director | 539 | — | — | $41.6K | 9 | 2018-01-08 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 1,048 | — | — | $0 | 3 | 2017-02-03 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Chief Executive Officer | 0 | — | — | -$1.16M | 10 | 2016-11-30 |
| GENZ | Exe VP,President Int'l Group | 35,171 | $37.11 | $1.31M | -$8.44M | 15 | 2011-04-06 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Director | 106,205 | $24.07 | $2.56M | $0 | 5 | 2008-07-11 |
Recent Filings · Page 10 of 11
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-05-25 | GENZ | Mixed | +3,225 | -$74.6K | EDGAR |
| 2010-03-23 | GENZ | Sell (S) | −3,359 | -$197.8K | EDGAR |
| 2009-05-27 | GENZ | Mixed | +3,359 | -$92.8K | EDGAR |
| 2009-05-26 | GENZ | Grant (A) | — | $0 | EDGAR |
| 2008-07-11 | ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-27 | GENZ | Grant (A) | — | $0 | EDGAR |
| 2008-01-22 | ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-01-18 | GENZ | Mixed | — | -$550.2K | EDGAR |
| 2008-01-15 | GENZ | Mixed | — | -$157.9K | EDGAR |
| 2008-01-11 | GENZ | Mixed | — | -$3.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.